TW201139375A - Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester - Google Patents

Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester Download PDF

Info

Publication number
TW201139375A
TW201139375A TW100100201A TW100100201A TW201139375A TW 201139375 A TW201139375 A TW 201139375A TW 100100201 A TW100100201 A TW 100100201A TW 100100201 A TW100100201 A TW 100100201A TW 201139375 A TW201139375 A TW 201139375A
Authority
TW
Taiwan
Prior art keywords
asthma
bronchitis
receptor
hydrochloride salt
inhibitor
Prior art date
Application number
TW100100201A
Other languages
English (en)
Chinese (zh)
Inventor
Kim James
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of TW201139375A publication Critical patent/TW201139375A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW100100201A 2010-01-07 2011-01-04 Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester TW201139375A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29297110P 2010-01-07 2010-01-07

Publications (1)

Publication Number Publication Date
TW201139375A true TW201139375A (en) 2011-11-16

Family

ID=43759799

Family Applications (1)

Application Number Title Priority Date Filing Date
TW100100201A TW201139375A (en) 2010-01-07 2011-01-04 Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester

Country Status (4)

Country Link
JP (1) JP2011153136A (ja)
AR (1) AR079835A1 (ja)
TW (1) TW201139375A (ja)
WO (1) WO2011083387A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201404522VA (en) * 2012-03-13 2014-10-30 Respivert Ltd Crystalline pi3 kinase inhibitors
MX2019004602A (es) * 2016-10-20 2019-06-17 Pfizer Agentes anti-proliferativos para tratar pah.
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB0315509D0 (en) 2003-07-02 2003-08-06 Meridica Ltd Dispensing device
US7320990B2 (en) * 2004-02-13 2008-01-22 Theravance, Inc. Crystalline form of a biphenyl compound
US7629336B2 (en) * 2005-03-10 2009-12-08 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TWI372749B (en) * 2005-03-10 2012-09-21 Theravance Inc Crystalline forms of a biphenyl compound
US7642355B2 (en) 2005-03-10 2010-01-05 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
CN102099334A (zh) * 2008-07-15 2011-06-15 辉瑞有限公司 作为蕈毒碱受体拮抗剂的新颖化合物

Also Published As

Publication number Publication date
AR079835A1 (es) 2012-02-22
JP2011153136A (ja) 2011-08-11
WO2011083387A1 (en) 2011-07-14

Similar Documents

Publication Publication Date Title
ES2869277T3 (es) Formas sólidas de un inhibidor selectivo de CDK4/6
JP4277051B2 (ja) ５−［３−（３−ヒドロキシフェノキシ）アゼチジン−１−イル］−５−メチル−２，２−ジフェニルヘキサンアミド塩酸塩
KR20100049688A (ko) Ｎ4-(2,2-다이플루오로-4ｈ-벤조[1,4]옥사진-3-온)-6-일]-5-플루오로-ｎ2-[3-(메틸아미노카보닐메틸렌옥시)페닐]2,4-피리미딘다이아민의 지나포에이트 염
TW200823185A (en) Sulfonamide derivatives
TW200806615A (en) Amine derivatives
AU2023200327A1 (en) Compounds
JP2001511766A (ja) 新規アミノピペラジン誘導体
BRPI0707559B1 (pt) polimorfo de forma i do sal de ácido succínico de 1- [2- (2- cloro- 4- {[(r)- 2- hidróxi- 2- (8- hidróxi- 2- oxo- 1,2- diidroquinolin- 5- il) etilamino] meti1]}- 5- metoxifenilcarbamoil) etil] piperidin- 4- il éster de ácido bifenil- 2- il- carbâmico, seu processo de preparo e usos
JPWO2003002554A1 (ja) ピペラジン化合物
KR20100108409A (ko) 염증성 질환을 치료하기 위한 [1,2,4]트라이아졸로[4,3-ａ]피리딘 유도체의 다형체 형태
TW201139375A (en) Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
TW201006799A (en) Novel compounds active as muscarinic receptor antagonists
ES2340220T3 (es) Derivados de azetidina como agentes antagonistas del receptor muscarinico.
JP4566259B2 (ja) 治療用化合物のトシル酸塩およびその医薬組成物
TWI257389B (en) Pharmaceutical compound
WO2023225601A2 (en) Ripk2 and nod inhibitors
TW200914024A (en) Mono-hydrochloric salts of an inhibitor of histone deacetylase
TW200403063A (en) Novel compounds
TW201309641A (zh) 新的ＣＲＴｈ２拮抗劑